Cognitive Symptoms

Though classified as a movement disorder, PD also affects thinking, learning, processing speed, reasoning, and other cognitive abilities. Cognitive symptoms present in a range from mild impairments including early mild frontal-executive dysfunction and memory deficits to more acute deficits such as bradyphrenia and dementia (Levin and Katzen, 2005; Rippon and Marder, 2005; Caviness et al., 2007). Community-based studies suggest that 30-40% of PD patients will develop clinically-defined dementia (Poewe, 2008).

Reference: 
Levin BE, Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Advances in neurology. 2005;96:84-94.
0
Rippon GA, Marder KS. Dementia in Parkinson's disease. Advances in neurology. 2005;96:95-113.
0
Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007;22(9):1272-7.
0
Responses:
Commentary on Palminter et al. (2009) Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes
Michael J Frank, Brown
28 Oct 2009 09:46 AM EST
Several studies have shown that cognitive reinforcement learning processes are altered in Parkinson's disease, and are particularly sensitive to effects of dopaminergic medication. While off ... 
Contributions:
Session Summary: Exercise interventions across gait and mental disorders
Gait & Movement Disorder Congress 2010
Mark Hallett, NINDS
05 Mar 2010
Dr. J. Hausdorff began by noting the general theme of the congress that gait requires cognition.  As gait becomes less automatic, for example, it requires more attention.  He demonstrated ... 
Commentary on Palminter et al. (2009) Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes
Cognitive Symptoms
Michael J Frank, Brown
28 Oct 2009
Several studies have shown that cognitive reinforcement learning processes are altered in Parkinson's disease, and are particularly sensitive to effects of dopaminergic medication. While off ... 
How do we define mild cognitive impairment (MCI)?
Are existing psychiatric and cognitive assessment scales adequate for use in clinical trials of PD treatments? Do better PD-specific scales need to be developed, and how can they be validated?
Holli Kawadler, MJFF
08 Oct 2009
An interesting discussion arose at a recent MJFF Awardee Meeting regarding assessing mild cognitive impairment in Parkinson's disease (PD-MCI). Cognition decribes a very complex set of functions, but ... 
more
Grant Opportunities:
Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (SBIR [R43/R44])
30 Jun 2009
The purpose of this PA is to encourage small businesses to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to better ... 
Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (STTR [R41/R42])
30 Jun 2009
The purpose of this FOA is to encourage small businesses to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to better ... 
Research on the Cognitive Sequelae of Parkinson’s Disease (R21)
11 Jun 2009
Brief Description:Under this Funding Opportunity Announcement (FOA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National ... 
Events:
The 3rd International Congress on Gait & Mental Function
08 Jun 2009
Washington, DC, USA ... 
6th International Congress on Vascular Dementia
24 Mar 2009
Barcelona, Spain Contact: KENES International, 1-3 rue de Chantepoulet, P.O. Box 1726, CH-1211 Geneva 1, Switzerland; TEL: +41-22-908-0488; FAX: +41-22-732-2850; E-mail: vascular@kenes.com Web site: www.kenes.com/vascular ... 
News:
2010 ADDF/ LBDA Lewy Body Dementia Biomarker Research Award
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Lewy Body Dementia Association (LBDA) are issuing a Request for Proposals for the 2010 ADDF/LBDA Lewy Body Dementia Biomarker Research ... 
08 Sep 2009
ADDF and AFTD announce Request for Proposals: Frontotemporal Dementia Drug Discovery Program
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this ... 
27 Aug 2009
Responses: 1
Prefrontal and striatal dopaminergic genes predict decision-making
Genes controlling dopaminergic function in the striatum and prefrontal cortex can predict decision-making behavior, shown by Frank et al. in Nature Neuroscience. Dr. Michael J. Frank, first author of ... 
14 Aug 2009
more
Related Clinical Trials:
Sarizotan in the Treatment of Neuroleptic-Induced Tardive Dyskinesia
31 May 2009
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the ... 
Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease
31 May 2009
The purpose of this study is to investigate how changes in the brain associated with Parkinson's disease influence the control of motor and thinking speed. There is disagreement over whether patients ... 
Donepezil to Treat Dementia in Parkinson's Disease
31 May 2009
This study will evaluate the safety and effectiveness of donepezil (Aricept) for treating mild dementia in patients with Parkinson's disease. Donepezil is approved for treating patients with ... 
more
Related Citations:
Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors
19 Jan 2010
 ... 
Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors
19 Jan 2010
 ...